Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Prioritizes Priority

Executive Summary

FDA's Office of New Drugs issues policy to expedite an NDA, BLA or efficacy supplement classification. The revised review classification policy now directs divisions to identify whether an application may qualify for a priority designation within 14 days of an application's receipt. If a priority designation is expected, the filing meeting to determine the review classification and first-cycle review timeline should occur by day 30 instead of day 45, the standard review date, a July 16 1Manual of Policies and Procedures states...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS048617

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel